07 LC 33
1948S
House
Bill 127 (RULES COMMITTEE SUBSTITUTE)
By:
Representatives Byrd of the
20th,
Jerguson of the
22nd,
Ehrhart of the
36th,
Rynders of the
152nd,
and Hill of the
21st
A
BILL TO BE ENTITLED
AN ACT
AN ACT
To
amend Article 5 of Chapter 4 of Title 26 of the Official Code of Georgia
Annotated, relating to prescription drugs, so as to change certain provisions
relating to the substitution of generic drugs; to eliminate redundant language
relating to the practice of medicine; to prohibit the substitution of
anti-epileptic drugs except under certain conditions; to provide for related
matters; to repeal conflicting laws; and for other purposes.
BE
IT ENACTED BY THE GENERAL ASSEMBLY OF GEORGIA:
SECTION
1.
Article
5 of Chapter 4 of Title 26 of the Official Code of Georgia Annotated, relating
to prescription drugs, is amended by revising Code Section 26-4-81, relating to
substitution of generic drugs for brand name drugs, as follows:
"26-4-81.
(a)
In accordance with this Code section
and except as
otherwise provided in Code Section
26-4-81.1, a pharmacist may substitute a
drug with the same generic name in the same strength, quantity, dose, and dosage
form as the prescribed brand name drug product which is, in the
pharmacist´s reasonable professional opinion, pharmaceutically
equivalent.
(b)
If a practitioner of the healing arts prescribes a drug by its generic name, the
pharmacist shall dispense the lowest retail priced drug product which is in
stock and which is, in the pharmacist´s reasonable professional opinion,
pharmaceutically equivalent.
(c)
Substitutions as provided for in subsections (a) and (b) of this Code section
are authorized for the express purpose of making available to the consumer the
lowest retail priced drug product which is in stock and which is, in the
pharmacist´s reasonable professional opinion, both therapeutically
equivalent and pharmaceutically equivalent.
(d)
Whenever a substitution is made, the pharmacist shall record on the original
prescription the fact that there has been a substitution and the identity of the
dispensed drug product and its manufacturer. Such prescription shall be made
available for inspection by the board or its representative in accordance with
the rules of the board.
(e)
The substitution of any drug by a registered pharmacist pursuant to this Code
section does not constitute the practice of medicine.
(f)(e)
A patient for whom a prescription drug order is intended may instruct a
pharmacist not to substitute a generic name drug in lieu of a brand name
drug.
(g)(f)
A practitioner of the healing arts may instruct the pharmacist not to substitute
a generic name drug in lieu of a brand name drug by including the words 'brand
necessary' in the body of the prescription. When a prescription is a hard copy
prescription drug order, such indication of brand necessary must be in the
practitioner´s own handwriting and shall not be printed, applied by rubber
stamp, or any such similar means.
(h)(g)
The substitution of any drug by a registered pharmacist pursuant to this Code
section does not constitute the practice of medicine."
SECTION
2.
Said
article is further amended by inserting a new Code section to read as
follows:
"26-4-81.1.
(a)
As used in this Code section, the term:
(1)
'Anti-epileptic drug' means:
(A)
Any drug prescribed for the treatment of epilepsy; and
(B)
A drug used to treat or prevent seizures.
(2)
'Epilepsy' means a neurological condition characterized by recurrent
seizures.
(3)
'Interchange' means the substitution of one version of a drug for another,
including a generic version for the prescribed brand version, a different
formulation of the prescribed version, and a different drug for the product
prescribed.
(4)
'Seizure' means an acute clinical change secondary to a brief disturbance in the
electrical activity of the brain.
(b)
A pharmacist shall not interchange an anti-epileptic drug or formulation of an
anti-epileptic drug without prior notification to and written consent of the
prescribing physician; provided, however, that a pharmacist may substitute a
generic version by one manufacturer for a generic version by another
manufacturer if both such versions are AB rated by the federal Food and Drug
Administration."
SECTION
3.
All
laws and parts of laws in conflict with this Act are repealed.